MiMedx Group announced its support of CMS' new methodology for the reimbursement of skin substitutes in the hospital outpatient setting, which was released on Nov. 27.
Under the new Hospital Outpatient Prospective Payment System Final Rule, CMS will package the reimbursement for certain products used in advanced wound care with the related surgical procedure into a two-tier payment system.
MiMedx Group is an integrated developer, manufacturer and marketer of regenerative biomaterials and bioimplants processed from human amniotic membrane.
5 Ways Materials Management Information Systems Can Improve Surgery Center Supply Chain
Mazor Robotics' Sells Renaissance Spine System to Lawnwood Regional Medical Center
Alphatec Spine Posts $14.5M Q3 Loss After PurGen Device Discontinuation
Under the new Hospital Outpatient Prospective Payment System Final Rule, CMS will package the reimbursement for certain products used in advanced wound care with the related surgical procedure into a two-tier payment system.
MiMedx Group is an integrated developer, manufacturer and marketer of regenerative biomaterials and bioimplants processed from human amniotic membrane.
More Articles on Supply Chain:
5 Ways Materials Management Information Systems Can Improve Surgery Center Supply Chain
Mazor Robotics' Sells Renaissance Spine System to Lawnwood Regional Medical Center
Alphatec Spine Posts $14.5M Q3 Loss After PurGen Device Discontinuation